Camurus AB Announces Major Collaboration with Eli Lilly

Stockholm, June 4, 2025 — Camurus AB, a research-based pharmaceutical company listed on the Swedish Stock Exchange, has seen its stock surge following the announcement of a significant collaboration with the American pharmaceutical giant Eli Lilly. The partnership focuses on the development of long-acting therapies using Camurus’ innovative FluidCrystal® technology combined with Eli Lilly’s proprietary drug compounds.

Key Details of the Agreement

The collaboration agreement grants Eli Lilly exclusive global rights to develop and commercialize long-acting incretin therapies. This strategic move is expected to bolster Camurus’ position in the pharmaceutical industry, particularly in the areas of obesity and diabetes treatment. The deal is valued at up to $870 million in potential development and sales milestone payments, with Camurus eligible to receive mid-single-digit royalties on net sales.

Market Reaction

The news has been met with enthusiasm from investors and analysts alike. Camurus’ stock experienced a significant uptick, with predictions of an initial surge of 20-30% in its share price. Analysts from Nordea and SEB have both highlighted the strong positive reaction expected in the market, attributing it to the validation of Camurus’ technology and the potential for substantial financial gains.

Strategic Implications

Camurus’ CEO, Fredrik Tiberg, expressed excitement over the deal, describing it as a validation of their technology. The collaboration is seen as a pivotal moment for Camurus, potentially opening doors to further partnerships and advancements in therapeutic medications for various health issues, including cancer, endocrinology, pain, metabolic disease, and drug addiction.

Financial Overview

As of June 1, 2025, Camurus’ share price closed at 515.5 SEK, with a 52-week high of 715 SEK and a low of 483.8 SEK. The company boasts a market capitalization of 30.09 billion SEK and a price-to-earnings ratio of 55.79. The collaboration with Eli Lilly is expected to significantly impact these financial metrics positively.

Conclusion

The partnership between Camurus and Eli Lilly marks a significant milestone for Camurus, reinforcing its commitment to innovation and expanding its reach in the global pharmaceutical market. The deal not only underscores the potential of Camurus’ FluidCrystal® technology but also sets the stage for future growth and development in the healthcare sector.